WaveMan
WaveMan · Company
ROIV · Roivant Sciences Ltd.
> Search tickers & screens ⌘K
LIVE
← All companies

ROIV Roivant Sciences (ROIV) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001635088
Quote by TradingView
Congress · 1Form 144 · 12
Insider buyers, 180 days
0
Funds added, last quarter
302
13F, latest reported quarter
Conversions, 180 days
18
Codes C/M, not in net · $12.0M priced

What the filings say about ROIV

Insiders, 180 days
-$269.8M net sold
7 sellers · 27% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 1 sold
Latest: sale, 2025-10-31
Planned sales (Form 144), 90 days
$59.9M
12 notices

Roivant Sciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Roivant Sciences Ltd. insiders sold a net $269.8M of stock across 301 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Venker Eric
President & Immunovant CEO
SELL
2026-10-22 SECtraded 2026-10-20
185,856
$6.5M
n/a
Context
  • 91 earlier Form 4 trades (code P or S) here by this insider (91 sales), the last on Sep 30, 2026.
  • The trade is 13.2% of the 1,413,298 shares held after it.
  • 1 other insider sold within 30 days.
  • 302 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & Immunovant CEO Venker Eric sold about $6.5M of ROIV under a 10b5-1 plan on Oct 20, 2026; 1 other insider sold within 30 days and 302 funds added in the latest 13F quarter.
Venker Eric
President & Immunovant CEO
SELL
2026-10-22 SECtraded 2026-10-20
14,144
$501.0K
n/a
Context
  • 91 earlier Form 4 trades (code P or S) here by this insider (91 sales), the last on Sep 30, 2026.
  • The trade is 1.0% of the 1,399,154 shares held after it.
  • 1 other insider sold within 30 days.
  • 302 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & Immunovant CEO Venker Eric sold about $501.0K of ROIV under a 10b5-1 plan on Oct 20, 2026; 1 other insider sold within 30 days and 302 funds added in the latest 13F quarter.
Epperly Melissa B,
Director
SELL
2026-10-05 SECtraded 2026-10-01
16,850
$607.9K
+2.7%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Sep 15, 2026.
  • The trade is 106.3% of the 15,854 shares held after it.
  • 2 other insiders sold within 30 days.
  • 302 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Epperly Melissa B, sold about $607.9K of ROIV under a 10b5-1 plan on Oct 1, 2026; 2 other insiders sold within 30 days and 302 funds added in the latest 13F quarter.
Epperly Melissa B,
Director
SELL
2026-10-05 SECtraded 2026-10-01
900
$32.9K
+2.7%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Sep 15, 2026.
  • The trade is 6.0% of the 14,954 shares held after it.
  • 2 other insiders sold within 30 days.
  • 302 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Epperly Melissa B, sold about $32.9K of ROIV under a 10b5-1 plan on Oct 1, 2026; 2 other insiders sold within 30 days and 302 funds added in the latest 13F quarter.
Venker Eric
President & Immunovant CEO
SELL
2026-10-02 SECtraded 2026-09-30
200,000
$7.3M
+2.0%
Context
  • 90 earlier Form 4 trades (code P or S) here by this insider (90 sales), the last on Aug 28, 2026.
  • The trade is 12.5% of the 1,599,154 shares held after it.
  • 2 other insiders sold within 30 days.
  • 302 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & Immunovant CEO Venker Eric sold about $7.3M of ROIV under a 10b5-1 plan on Sep 30, 2026; 2 other insiders sold within 30 days and 302 funds added in the latest 13F quarter.
301 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 296 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$269.8M over 180 days
-$59.9M over 90 days
below 99% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
302 funds bought in last quarter
more than 95% of Pharma & Biotech
Revenue
-71.6% year over year
below 85% of Pharma & Biotech
Margin
-3629.2% net margin
below 94% of Pharma & Biotech
Buybacks
$206.7M repurchased, FY to 2026-06-30
more than 77% of Pharma & Biotech
Short interest
6.8% of the float short (float per yahoo 2026-10-26) · 4.4 days to cover · settled 2026-09-30
more than 53% of Pharma & Biotech
What changed in the last 30 days
Oct 22President & Immunovant CEO Venker Eric sold $14.3M under a 10b5-1 plan (3 trades, Sep 30 to Oct 20)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 20Officer Venker Eric filed to sell $7.0M by Oct 20 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 5Director Epperly Melissa B, sold $640.9K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Sep 30Officer Venker Eric filed to sell $7.3M by Sep 30 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch ROIV

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+103.2%12M
+0%+44%+89%+133%2025-102025-122026-022026-042026-062026-082026-10 2025-12-12 · Ramaswamy Vivek sold $43.4M2026-02-19 · Torti Frank sold $38.4M2026-02-20 · Torti Frank sold $27.5M2025-12-31 · Sukhatme Mayukh sold $22.1M2025-11-14 · Ramaswamy Vivek sold $20.9M2026-06-29 · MANCHESTER KEITH S sold $20.8M2026-06-29 · Gold Daniel Allen sold $20.8M2026-06-29 · QVT Financial LP sold $20.8M2025-12-15 · Gline Matthew sold $20.5M2025-11-19 · MANCHESTER KEITH S sold $17.2M2025-11-19 · Gold Daniel Allen sold $17.2M2025-11-19 · QVT Financial LP sold $17.2M2026-06-25 · Sukhatme Mayukh sold $17.1M2026-06-26 · Sukhatme Mayukh sold $17.0M2025-12-11 · Ramaswamy Vivek sold $16.8M2026-02-23 · Torti Frank sold $16.2M2025-12-16 · Gold Daniel Allen sold $14.8M2025-12-16 · MANCHESTER KEITH S sold $14.8M2025-12-16 · QVT Financial LP sold $14.8M2025-12-15 · Gline Matthew sold $12.3M2026-02-11 · MANCHESTER KEITH S sold $11.3M2026-02-11 · Gold Daniel Allen sold $11.3M2026-02-11 · QVT Financial LP sold $11.3M2026-06-26 · MANCHESTER KEITH S sold $11.1M2026-06-26 · Gold Daniel Allen sold $11.1M2026-06-26 · QVT Financial LP sold $11.1M2025-11-17 · Ramaswamy Vivek sold $11.1M2026-08-17 · Sukhatme Mayukh sold $10.3M2026-06-26 · MANCHESTER KEITH S sold $10.2M2026-06-26 · Gold Daniel Allen sold $10.2M2026-06-26 · QVT Financial LP sold $10.2M2025-12-17 · Gold Daniel Allen sold $10.0M2025-12-17 · MANCHESTER KEITH S sold $10.0M2025-12-17 · QVT Financial LP sold $10.0M2026-02-09 · Sukhatme Mayukh sold $9.0M2026-08-14 · Sukhatme Mayukh sold $8.8M2026-04-16 · Gline Matthew sold $8.4M2025-12-15 · Ramaswamy Vivek sold $7.8M2026-02-12 · MANCHESTER KEITH S sold $7.4M2026-02-12 · Gold Daniel Allen sold $7.4M2026-02-12 · QVT Financial LP sold $7.4M2026-09-30 · Venker Eric sold $7.3M2026-10-20 · Venker Eric filed to sell $7.0M2026-09-30 · Venker Eric filed to sell $7.3M2026-09-15 · MELISSA EPPERLY filed to sell $930.7K2026-09-15 · MEGHAN FITZGERALD filed to sell $209.7K2026-09-08 · MEGHAN FITZGERALD filed to sell $698.6K2026-08-28 · Venker Eric filed to sell $7.1M2026-08-21 · MAYUKH SUKHATME filed to sell $5.3M2026-08-20 · MAYUKH SUKHATME filed to sell $653.4K2026-08-19 · MAYUKH SUKHATME filed to sell $6.4M2026-08-18 · MAYUKH SUKHATME filed to sell $5.0M2026-08-17 · MAYUKH SUKHATME filed to sell $10.3M2026-08-14 · MAYUKH SUKHATME filed to sell $8.8M2026-07-27 · Venker Eric filed to sell $7.0M2026-06-30 · MEGHAN FITZGERALD filed to sell $347.3K2026-06-30 · KEITH S MANCHESTER filed to sell $7.1M2026-06-29 · MELISSA EPPERLY filed to sell $604.7K2026-06-26 · MAYUKH SUKHATME filed to sell $17.0M2026-06-25 · MAYUKH SUKHATME filed to sell $17.1M2026-06-24 · Venker Eric filed to sell $6.6M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ROIV: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
81,020,390 sh
$2.9B
BlackRock, Inc.
48,236,091 sh
$1.7B
MORGAN STANLEY
42,592,905 sh
$1.5B
QVT Financial LP
23,723,074 sh
$839.6M
VANGUARD CAPITAL MANAGEMENT LLC
22,123,198 sh
$782.9M

Congress trades in ROIV

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Lisa McClain
Sold 2025-10-31 · disclosed 21 days later
$1,001 - $15,000
Lisa McClain
Sold 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Lisa McClain
Bought 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Lisa McClain
Bought 2025-06-17 · disclosed 57 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ROIV planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Venker Eric
Filed 2026-10-20
$7.0M
Venker Eric
Filed 2026-09-30
$7.3M
MELISSA EPPERLY
Filed 2026-09-15
$930.7K
MEGHAN FITZGERALD
Filed 2026-09-15
$209.7K
MEGHAN FITZGERALD
Filed 2026-09-08
$698.6K

ROIV mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Dorsey Wright Healthcare Momentum ETF
$11.6M position · as of 2026-07-31
4.9%
AlphaCentric Life Sciences and Healthcare Fund
$1.7M position · as of 2026-06-30
3.7%
Invesco S&P MidCap Momentum ETF
$177.0M position · as of 2026-07-31
2.5%
Invesco Nasdaq Biotechnology ETF
$1.2M position · as of 2026-05-31
1.7%
Parnassus Mid Cap Growth Fund
$12.8M position · as of 2026-06-30
1.5%
Parnassus International Equity Fund
$196.3K position · as of 2026-06-30
1.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $269.8M sold by insiders over 180 days, 302 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $59.9M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ROIV financials

Revenue growth
-71.6%
XBRL, annual
Net margin
-3629.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$7.5M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-3,535%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$821.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.07x
LongTermDebt as filed 2024-06-30 (24 months older than the period end) (includes the current portion); equity 2026-06-30
Cash flow to debt
-2.62x
TTM operating cash flow over LongTermDebt as filed 2024-06-30 (24 months older than the period end) (includes the current portion)
Return on equity
-6.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-5.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-12.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$25.4B
market value at close 2026-10-23 on 2026-07-31 shares, plus LongTermDebt as filed 2024-06-30 (24 months older than the period end) (includes the current portion), minus cash 2026-06-30
FCF yield
-3.1%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-032025-032024-032023-03
Revenue$8.3M$29.1M$124.8M$61.3M
Operating income-$515.1M-$1.0B$4.5B-$906.8M
Net income-$299.8M-$172.0M$4.3B-$1.0B
EPS (diluted)-0.54-0.245.23-1.42
Operating cash flow-$750.3M-$839.5M-$765.3M-$843.4M
Cash$1.4B$2.7B$6.5B$1.7B
Long-term debtn/an/a$430.6M$375.5M
Buybacksn/a$1.3B$0$0
SEC XBRL, fiscal years, as known on 2026-10-27

ROIV Stock Sonar score 6/7 axes

Find similar shapesCompare

ROIV ranks highest on profitability (78th percentile) and institutional and government (64th), and lowest on insider conviction (1st), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
78
Inputs
  • Return on equity-6.2% · 78 pct, sector of 545
  • Return on assets-5.2% · 77 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-12.0% · 77 pct, sector of 576
Financial health
49
Inputs
  • Debt to equity0.07x · 58 pct, sector of 352
  • Cash flow to debt-2.62x · 40 pct, sector of 371
Growth
15
Inputs
  • Revenue growth, YoY-71.6% · 15 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
1
Inputs
  • Net Form 4 buying (codes P and S), 180d-$246.4M · 1 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
64
Inputs
  • Funds adding, latest quarter302 · 95 pct, sector of 698
  • Congress net buyers, 365d0 · 33 pct, sector of 49
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
37
Inputs
  • Short interest, % of float+6.8% · 50 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+17.7% · 23 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ROIV filings, in plain words

Are Roivant Sciences insiders buying or selling ROIV?

In the 180 days to 2026-10-27, Roivant Sciences insiders were net sellers, a net $269.8M across purchases and sales reported on Form 4, by 7 sellers.

Have members of Congress traded ROIV?

Yes. In the year to 2026-10-27, 1 House member disclosed buying ROIV and 1 House member disclosed selling it; the latest on record is a sale by Lisa McClain dated 2025-10-31.

Are there planned insider sales of ROIV?

Yes. 12 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $59.9M of stock; the latest, by Venker Eric, was filed 2026-10-20.

Read the full summary

In the 180 days to 2026-10-27, Roivant Sciences insiders were net sellers of ROIV, a net $269.8M across purchases and sales reported on Form 4 by 7 sellers. 27% of the 44 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-27, 1 member of Congress disclosed buying ROIV and 1 member disclosed selling it; the latest on record is a sale by Lisa McClain dated 2025-10-31. Insiders filed 12 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $59.9M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies